N/A
N=416
Partnering With WIC to Prevent Excessive Weight Gain in Pregnancy
Obesity · Overweight · Pregnancy Related
Bottom Line
View on ClinicalTrials.gov: NCT03707834 ↗Enrolled (actual)
416
Serious AEs
0.0%
Results posted
Jan 2026
Primary outcome: Primary: Percentage of Women With Excessive Gestational Weight Gain — 126; 119 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Antenatal Obesity Treatment (AO) (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Temple University
- Primary completion
- Oct 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Women With Excessive Gestational Weight Gain |
126; 119 | — |
| PRIMARY Change in Maternal Weight |
7.6; 7.2 | — |
| SECONDARY Change in Dietary Intake |
— | — |
| SECONDARY Percentage With Glucose Intolerance |
— | — |
| SECONDARY Percentage With Hypertension |
— | — |
| SECONDARY Change in Maternal 6-month Weight Postpartum (pp) |
— | — |
| SECONDARY Change in Maternal 12-month Weight Postpartum (pp) |
— | — |
Summary
The purpose of this study is to determine the effect of an antenatal obesity treatment on gestational weight gain when integrated into Philadelphia WIC.
Eligibility Criteria
Inclusion Criteria
- BMI ≥ 25 kg/m2
- Self-identify as African American or Hispanic
- Gestational age ≤16 weeks' (measured using last menstrual period)
- Philadelphia WIC participant
- Willingness to receive study texts
- Own a cell phone with an unlimited text messaging plan
- Able to participate in light to moderate physical activity (walking)
Exclusion Criteria
- Prior bariatric surgery
- Pre-existing medical condition that could influence weight (e.g., diabetes, HIV, thyroid disorder, bulimia, anorexia, gallbladder disease)
- Diagnosis contraindicating weight control (e.g., hyperemesis gravidarum)
- Shared phone
- Multiple pregnancy (e.g., twins)
- Current and/or previous participant for our Temple-led obesity treatment interventions in pregnancy or the postpartum period
- Serious or unstable medical or psychological conditions that, in the opinion of the PI, would compromise the subject's safety for successful participation in the study
Data sourced from ClinicalTrials.gov (NCT03707834). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.